30 closest matches · ranked by relevance
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Lymphoma
Primary: Objective Response Rate (ORR) — 64 percentage of participants
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
NSCLC · Crizotinib · ALK Gene Rearrangement or ROS1 Gene Rearrangement
Primary: Age: Line of Treatment — 62.3; 63.1; 56.5; 64.3 Years
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Neuroblastoma
Primary: Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib — 280 mg/m²/dose BID
Lymphoma, Large-Cell, Anaplastic · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate by Independent Review Group — 86 percent of participants
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator — 10.9; 1.4 months — p=<0.001
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I — 0; 0; 0; 0 participants
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Lymphoma
Primary: Event-free Survival (EFS) — 74; 79 percentage of participants
Non-Small Cell Lung Cancer
Primary: Primary Pharmacokinetics (PK) Parameters of of LDK378 After Daily Oral Dose: AUClast, AUC0-24h, AUCinf — 10100; 3940; 11100 ng*hr/mL
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) by Investigator Assessment — NA; 11.1 months — p=<0.0001
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Non-Small-Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 by Investigator Assessment — 25.0 Percentage of participants
Non-Small-Cell Lung Carcinoma
Primary: Recommended Phase 2 Dose (RP2D) of Alectinib
ALK-activated Tumors
Primary: Incidence Rate of Dose Limiting Toxicities (DLTs) Occurring During First Cycle of Treatment — 0; 0; 0; 1 Participants